GlassScriptPhysician profile
David Chachkhiani
NPI 1164953006
$12,324.24
in general payments reported to CMS, 2019-2025
39 companies · $3,299 in 2025
The $3,299 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $151 · 2021: $1,314 · 2022: $1,500 · 2023: $2,851 · 2024: $3,105 · 2025: $3,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,167 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,167.43 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,087.66 | 2022-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,408.94 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $1,004.22 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Acadia Pharmaceuticals INC | $882.54 | 2022-2025 | Nuplazid |
| Sk Life Science, INC. | $743.22 | 2022-2025 | Xcopri |
| Catalyst Pharmaceuticals, INC. | $678.60 | 2021-2023 | Fycompa |
| Argenx US, INC. | $603.75 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurelis, INC. | $588.19 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $552.48 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $450.49 | 2023-2025 | |
| Lundbeck LLC | $398.15 | 2022-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $383.90 | 2021-2025 | Ultomiris, Soliris |
| Jazz Pharmaceuticals INC. | $372.21 | 2022-2025 | |
| Emd Serono, INC. | $245.66 | 2020-2024 | Mavenclad |
| Astrazeneca Pharmaceuticals LP | $210.99 | 2021-2025 | Wainua |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $202.48 | 2022-2023 | |
| Genentech USA, INC. | $195.73 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $142.39 | 2022-2025 | Rytary, Crexont |
| Csl Behring | $139.38 | 2020-2024 | Hizentra |
| Abbott Laboratories | $128.87 | 2024-2025 | Jot Dx, Confirm Rx |
| Mallinckrodt Hospital Products INC. | $99.74 | 2023-2025 | Acthar |
| Aucta Pharmaceuticals, INC. | $93.39 | 2024-2025 | Motpoly Xr |
| Celgene Corporation | $87.49 | 2020-2024 | Zeposia |
| Grifols USA, LLC | $83.12 | 2024-2025 | Gamunex-C |
| Eisai INC. | $70.72 | 2025 | |
| Amgen INC. | $56.08 | 2021-2025 | Uplizna |
| Janssen Biotech, INC. | $53.37 | 2025 | |
| Merz Pharmaceuticals, LLC | $52.62 | 2025 | Xeomin, Inbrija, Ampyra |
| Biogen, INC. | $44.60 | 2024-2025 | Leqembi, Skyclarys |
| Biohaven Pharmaceutical Holding Company LTD. | $40.96 | 2022 | |
| Portola Pharmaceuticals, LLC | $37.89 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $35.30 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $33.40 | 2024-2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $28.23 | 2024 | Onpattro |
| Sumitomo Pharma America, INC. | $20.15 | 2023 | Aptiom |
| Adamas Pharmaceuticals, INC. | $19.23 | 2020 | |
| Tg Therapeutics, INC. | $18.94 | 2023 | |
| Arbor Pharmaceuticals, INC. | $15.91 | 2022 | |
| Impel Pharmaceuticals INC. | $13.25 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chachkhiani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.